

Press release



U-Protein Express acquires a major stake in QVQ.

Utrecht, The Netherlands, March 17th 2017 – U-Protein Express is a dedicated service provider in the field of production and purification of fully post translational modified mammalian proteins and antibodies via its r-PEx technology platform that is based on HEK and CHO cells. Today U-Protein Express announces that it has acquired a major stake in QVQ, a promising nanobody-focused company. With this investment, U-Protein Express is now the company's second largest shareholder.

QVQ offers the following services: design and implementation of a Llama immunization protocol, measuring immune response in the sera of the immunized Llamas, VHH-phage display library construction, design and implement a selection strategy, delivery of the sequence and 0.5 mg purified VHH of a number of unique VHH molecules suitable for follow up assays.

“With QVQ we will be able to better serve our mutual and new customers by enhancing our product service portfolio and strengthening our position in the antibody generation and production service market.” said Martin Hessing, Executive Director U-protein Express. Like U-Protein Express, QVQ is located on the Utrecht Science Park, The Netherlands.

For more information please contact Dr. Martin Hessing, at M.Hessing@U-ProteinExpress.com.